Protagen

What Protagen does

ProtaGene GmbH (operating under the trade names ProtaGene and ProtaGene Group; the legal entity originated as Protagen, founded in 1997 in Dortmund, Germany) is a privately-held, multi-continent analytical services provider serving global biopharmaceutical, cell, and gene therapy developers. The company is headquartered in Heilbronn, Germany, with a North American headquarters in Burlington, Massachusetts, and is structured as a German private limited company (GmbH). It operates without disclosed external institutional ownership, parent company, or public listing. Headcount is reported in the 11-50 range.

The company's offering is organized into two core service lines. Biologic Drug Analytics spans biologics analytical development, biotherapeutic characterization, biosimilar testing, cell-based assays, GMP-compliant manufacturing and QC, and clinical sample in vivo CQA mapping. Cell & Gene Therapeutic Analytics covers molecular bioanalysis, integration site analysis (ISA), vector characterization, long-read sequencing, NGS bioinformatics, genome and gene editing analysis, gene expression quantitation, and commercial patient testing. Underlying technology platforms include LC-MS and LC-MS/MS, cell-based bioassays, and next-generation sequencing with bioinformatics. Services are delivered under GMP-compliant quality systems and are designed to support IND and BLA submissions, lot release, and long-term follow-up (LTFU) studies for gene therapy.

ProtaGene generates revenue through professional-services contracts with enterprise biopharma and CGT sponsors across preclinical, clinical, and commercial stages. Pricing is quote-based and not publicly disclosed; the go-to-market is consultative enterprise field sales, initiated through 30-minute introductory calls, supported by technical content marketing (webinars, whitepapers, fact sheets), organic social (LinkedIn, Instagram), and direct engagement. Use cases span biologic candidate evaluation through IND, Phase I-III characterization packages for BLA acceleration, registration and market comparability testing, gene therapy vector analytics, integration site analysis for LTFU monitoring, and commercial patient testing. The company also holds an Ecovadis Silver sustainability certification (2025).

Name

Protagen

Legal name

ProtaGene GmbH

Website

https://protagen.com

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

11–50 employees

Short description

ProtaGene is a privately-held, multi-continent analytical services provider offering GMP-compliant biologics and cell & gene therapy characterization (LC-MS, cell-based assays, NGS bioinformatics) to global biopharmaceutical developers from discovery through commercial release.

Ownership category

akta.pro rank

Product category

Bioanalytical Services

NAICS

Medical Laboratories (621511), Scientific Research and Development Services (5417)

SIC

Services-Testing Laboratories (8734)

akta.pro primary industry

Proteomics & Mass Spectrometry Services (HLAGANAB)

akta.pro secondary industries

Cell-Based & Potency Assays (Bioassays) (HLAGADAH), DMPK / ADME & Bioanalysis (HLAGAFAC), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ)

Keywords

• Biologics analytical services
• Cell and gene therapy analytics
• Vector characterization services
• GMP-compliant bioanalysis
• Biosimilar characterization testing

Headquarters

HQ city

Dortmund

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Analytical Services Revenue: ProtaGene generates revenue through providing analytical testing and characterization services to biopharmaceutical companies throughout the drug development lifecycle—from discovery through commercial product release. Services include biologics analytical development, biotherapeutic characterization, biosimilar testing, cell-based assays, and GMP-compliant manufacturing/QC support.
2. Consultation Services: Expert consultation services provided to support client decision-making throughout the development process, including program partnering services for specialized support.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Protagen provides advanced analytical testing and characterization services for biopharmaceutical and cell & gene therapy developers across the full development lifecycle. The company's two core service lines are Biologic Drug Analytics (biologics analytical development, biotherapeutic characterization, biosimilar testing, cell-based assays, manufacturing/QC, and clinical sample CQA mapping) and Cell & Gene Therapeutic Analytics (molecular bioanalysis, integration site analysis, vector characterization, long-read sequencing, bioinformatics, genome/gene editing analysis, gene expression quantitation, and commercial patient testing).

Product overview

ProtaGene is a multi-continent analytical services company providing integrated analytical solutions for biopharmaceutical, cell, and gene therapy developers. The portfolio consists of two core service lines: Biologic Drug Analytics (including Biologics Analytical Development, Biotherapeutic Characterization, Biosimilar Testing, Cell-Based Assays, Manufacturing and QC, and Clinical Sample In Vivo CQA Mapping) and Cell & Gene Therapeutic Analytics (including Molecular Bioanalysis, Integration Site Analysis, Vector Characterization, Long-Read Sequencing, Bioinformatics – NGS Data Analytics, Genome and Gene Editing, Gene Expression Quantitation, and Commercial Patient Testing). These services span from research through commercial-stage product release, supporting clients through discovery, preclinical, Phase I-III clinical trials, and registration to market.

Differentiator

Problem solved

Functional benefit

Products and services

• Biologic Drug Analytics Comprehensive analytical services for biotherapeutic development across all stages, including biologics analytical development, biotherapeutic characterization, biosimilar testing, cell-based assays, GMP-compliant manufacturing/QC, and clinical sample in vivo CQA mapping. Aimed at global biopharmaceutical companies developing biologics, monoclonal antibodies, antibody drug conjugates (ADCs), and biosimilars.
• Cell & Gene Therapeutic Analytics Industry-leading vector analytics and bioanalytical services for cell and gene therapy developers, including molecular bioanalysis, integration site analysis (ISA) for long-term follow-up monitoring, vector characterization, long-read sequencing, bioinformatics NGS data analytics, genome and gene editing analysis, gene expression quantitation, and commercial patient testing. Targeted at cell and gene therapy developers requiring safety-focused analytics.

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Direct peers

• KCAS Bioanalytical: KCAS is a specialized bioanalytical CRO offering LC-MS/MS and ligand-binding assays for biologics, biosimilars, and cell/gene therapies—a directly comparable niche peer in mass spec–driven analytical services for biopharma.
• BioAgilytix: BioAgilytix is a specialized bioanalytical CRO focused on large molecule biologics and cell/gene therapy characterization, offering LC-MS/MS, cell-based assays, and immunogenicity testing—closely overlapping ProtaGene's core biologics and CGT analytics menu for biopharma clients.

Broad incumbents

• Charles River Laboratories: Charles River provides comprehensive CRO/CDMO services including biologics testing, cell-based assays, and increasingly CGT analytical services—making it a broad incumbent competing for the same biopharma analytical services spend.
• WuXi AppTec (WuXi Biologics): WuXi AppTec and WuXi Biologics offer global biologics analytical development, characterization, and biosimilar testing at scale, representing a major low-cost incumbent with overlapping service capabilities and significantly larger capacity.
• Eurofins Scientific: Eurofins is a global testing services conglomerate with significant pharmaceutical and biopharmaceutical product testing capabilities, including biologics characterization and CGT analytics, serving as a broad incumbent competitor across many of ProtaGene's service lines.
• Thermo Fisher Scientific (PPD): Thermo Fisher, through PPD and its pharma services segment, offers end-to-end CRO services including bioanalytical, biologics characterization, and CGT analytics at global scale—representing a top-tier incumbent competing for enterprise-level biopharma analytical work.
• Lonza: Lonza is a leading CDMO with extensive biologics testing and analytical development services and has been actively expanding CGT analytical capabilities—directly contesting ProtaGene's mid-market position with greater scale.
• Catalent: Catalent provides biologics analytical services and cell/gene therapy development capabilities across a broad portfolio, competing with ProtaGene for biopharmaceutical and CGT analytical engagements.
• SGS Health Sciences: SGS's Health Sciences division offers bioanalytical, biologics characterization, and GMP testing services to biopharmaceutical clients globally, providing comparable analytical services with a much larger geographic and operational footprint.

Emerging players

• Sartorius: Sartorius offers bioprocess analytics and bioanalytical instruments/services for biologics manufacturers; while primarily an equipment provider, its expanding services and analytics offerings increasingly overlap with ProtaGene's characterization work.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/protagene
• Instagraminstagram.com/protagene_group?igsh=MW1qZWNoNmpmcTE4cA==

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds6 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Protagen